Supply chains put the places a medicine can fail beyond the reach of its licence

The argument

A second argument offered for this position concerns where a modern medicine actually comes from. A finished tablet is the end of a chain: an active ingredient synthesised in one country from intermediates made in another, excipients and solvents bought on open markets, packaging and sterilisation often subcontracted, and the whole assembled by a company that may manufacture nothing itself. Proponents note that a licence is granted to a product and to the company holding the authorisation, not to this chain, and that most of the chain has no direct relationship with the regulator at all. The argument is that the system is thinnest exactly where the risk concentrates. A single plant making an active ingredient may supply many finished products sold by competing companies under different brand names, so a defect at that one site propagates into dozens of apparently unrelated medicines at once. The authorisation holder may not know the identity of its supplier's supplier. Commercial pressure runs the wrong way, since the cheapest source is often the one furthest from oversight, and a company that changes supplier has an incentive to treat the change as routine. On this account the chain delivers both the savings that make generic medicines affordable and a concentration of risk that no individual licence is shaped to see. Holders of the view argue that inspection is the only part of the regulatory apparatus that follows a medicine into these places, and that it should therefore be the part the system is built around. Inspection can reach a subcontractor that never submitted a dossier, require a chain to be documented before a defect appears rather than after, and suspend a site rather than a product. Proponents accept that this is expensive and that it requires regulators to act beyond their own jurisdictions, and argue that the alternative is a system whose authority stops at a border the medicine itself crossed long ago.

Premises

Counter-arguments

Opponents argue that this describes a procurement and transparency problem rather than a case for making inspection the centre of regulation. The remedies that address it most directly are requirements to declare and document the chain, liability placed firmly on the authorisation holder, and competition rules that prevent a single site becoming a universal supplier, none of which require a regulator to constitute itself as an inspectorate. Others point out that the reach this position asks for does not exist, since a regulator cannot inspect its way through every jurisdiction a chain passes through, and a priority that depends on an authority nobody holds is not a workable organising principle.

Rejecting the premises

[Rejecting P2] Authorisation holders are in practice made contractually and legally answerable for their suppliers, so the licence does reach the chain, if indirectly. [Rejecting P3] Concentration at a single upstream site is a feature of particular markets rather than a general property of supply chains, and competition rules can address it directly. [Rejecting C] Inspection cannot in fact follow a chain through every jurisdiction it passes through, so the conclusion rests on a reach no regulator possesses.